Dibromdulcitol containing chemotherapeutic regimen in the treatment of childhood Hodgkin's disease.
Dibromdulcitol containing modified MOPP chemotherapeutic regimen plus radiotherapy were used in 58 children with Stage I-IV Hodgkin's disease diagnosed between 1975 and 1985 in Hungary. A remission rate of 93.1% and a 5-year relapse-free survival of 89% was observed. Some latent hyperthyreoidism as late effect of the therapy, no growth disturbances and no adverse gonadal effects were seen until now.